RNAi Litigation

(1) Max-Planck, Alnylam v. Whitehead Inst., MIT, Univ. Mass & (2) Tekmira v. Alnylam & (3) Univ. Utah v. Max-Planck, Alnylam, Whitehead Inst., MIT, Univ. Mass

September 2010
S	M	T	W	T	F	S
« Aug		Oct »
	1	2	3	4
5	6	7	8	9	10	11
12	13	14	15	16	17	18
19	20	21	22	23	24	25
26	27	28	29	30

Archive for September 30th, 2010

Benitec Wins Important Victory at the USPTO

September 30th, 2010 |

Author: johnleavitt

Multiple court documents will be posted tomorrow, Friday, October 1.

Today, Benitec Limited in Melbourne Australia announced the USPTO Board of Patent Appeals and Interferences decision reversing all previous claim rejections for US 6,573,099, a basic patent covering DNA-directed RNAi interference in humans (the “Graham patent”). Benitec appears to own gene therapy for RNA interference with a June 19, 1998, priority date.

Here is the information on this decision posted at Benitec’s website www.benitec.com :

USPTO Board of Appeals Decision

Benitec’s Media Release

Benitec will now be able to extend their therapeutic programs in HIV/AIDS, Hepatitis B, and Lung Cancer.

See Dirk Haussecker’s discussion about this Benitec/CSIRO victory.

Posted in Uncategorized |

No Comments »

What is siRNA?

Elbashir etal. (left sidebar): "Double-stranded RNA (dsRNA) induces sequence-specific posttranscriptional gene silencing in many organisms by a process known as RNA interference (RNAi) ... 21- and 22-nt RNA fragments are the sequence-specific mediators of RNAi. The short interfering RNAs (siRNAs) are generated by an RNase III–like processing reaction from long dsRNA. Chemically synthesized siRNA duplexes with overhanging 3' ends mediate efficient target RNA cleavage ..." and "... (these) 21-nucleotide siRNA duplexes specifically suppress expression of endogenous and heterologous genes in different mammalian cell(s)..."